Abstract
Keratins are the intermediate filament (IF)-forming proteins of epithelial cells. Since their initial characterization almost 30 years ago, the total number of mammalian keratins has increased to 54, including 28 type I and 26 type II keratins. Keratins are obligate heteropolymers and, similarly to other IFs, they contain a dimeric central α-helical rod domain that is flanked by non-helical head and tail domains. The 10-nm keratin filaments participate in the formation of a proteinaceous structural framework within the cellular cytoplasm and, as such, serve an important role in epithelial cell protection from mechanical and non-mechanical stressors, a property extensively substantiated by the discovery of human keratin mutations predisposing to tissue-specific injury and by studies in keratin knockout and transgenic mice. More recently, keratins have also been recognized as regulators of other cellular properties and functions, including apico-basal polarization, motility, cell size, protein synthesis and membrane traffic and signaling. In cancer, keratins are extensively used as diagnostic tumor markers, as epithelial malignancies largely maintain the specific keratin patterns associated with their respective cells of origin, and, in many occasions, full-length or cleaved keratin expression (or lack there of) in tumors and/or peripheral blood carries prognostic significance for cancer patients. Quite intriguingly, several studies have provided evidence for active keratin involvement in cancer cell invasion and metastasis, as well as in treatment responsiveness, and have set the foundation for further exploration of the role of keratins as multifunctional regulators of epithelial tumorigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anderson JM, Heindl LM, Bauman PA, Ludi CW, Dalton WS, Cress AE . (1996). Cytokeratin expression results in a drug-resistant phenotype to six different chemotherapeutic agents. Clin Cancer Res 2: 97–105.
Ashkenazi A . (2008). Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7: 1001–1012.
Ausch C, Buxhofer-Ausch V, Olszewski U, Hinterberger W, Ogris E, Schiessel R et al. (2009). Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients. Eur J Surg Oncol 35: 1164–1168.
Baribault H, Penner J, Iozzo RV, Wilson-Heiner M . (1994). Colorectal hyperplasia and inflammation in keratin 8-deficient FVB/N mice. Genes Dev 8: 2964–2973.
Baribault H, Price J, Miyai K, Oshima RG . (1993). Mid-gestational lethality in mice lacking keratin 8. Genes Dev 7: 1191–1202.
Baribault H, Wilson-Heiner M, Muller W, Penner J, Bakhiet N . (1997). Functional analysis of mouse keratin 8 in polyoma middle T-induced mammary gland tumours. Transgenic Res 6: 359–367.
Bauman PA, Dalton WS, Anderson JM, Cress AE . (1994). Expression of cytokeratin confers multiple drug resistance. Proc Natl Acad Sci USA 91: 5311–5314.
Beil M, Micoulet A, von Wichert G, Paschke S, Walther P, Omary MB et al. (2003). Sphingosylphosphorylcholine regulates keratin network architecture and visco-elastic properties of human cancer cells. Nat Cell Biol 5: 803–811.
Bluemke K, Bilkenroth U, Meye A, Fuessel S, Lautenschlaeger C, Goebel S et al. (2009). Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers Prev 18: 2190–2194.
Bonifas JM, Rothman AL, Epstein Jr EH . (1991). Epidermolysis bullosa simplex: evidence in two families for keratin gene abnormalities. Science 254: 1202–1205.
Bragulla HH, Homberger DG . (2009). Structure and functions of keratin proteins in simple, stratified, keratinized and cornified epithelia. J Anat 214: 516–559.
Buning C, Halangk J, Dignass A, Ockenga J, Deindl P, Nickel R et al. (2004). Keratin 8 Y54H and G62C mutations are not associated with inflammatory bowel disease. Dig Liver Dis 36: 388–391.
Casanova ML, Bravo A, Martinez-Palacio J, Fernandez-Acenero MJ, Villanueva C, Larcher F et al. (2004). Epidermal abnormalities and increased malignancy of skin tumors in human epidermal keratin 8-expressing transgenic mice. FASEB J 18: 1556–1558.
Casanova ML, Bravo A, Ramirez A, Morreale de Escobar G, Were F, Merlino G et al. (1999). Exocrine pancreatic disorders in transsgenic mice expressing human keratin 8. J Clin Invest 103: 1587–1595.
Cavestro GM, Frulloni L, Nouvenne A, Neri TM, Calore B, Ferri B et al. (2003). Association of keratin 8 gene mutation with chronic pancreatitis. Dig Liver Dis 35: 416–420.
Chan R, Rossitto PV, Edwards BF, Cardiff RD . (1986). Presence of proteolytically processed keratins in the culture medium of MCF-7 cells. Cancer Res 46: 6353–6359.
Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK et al. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368–1376.
Chen N, Gong J, Chen X, Xu M, Huang Y, Wang L et al. (2009). Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA. Melanoma Res 19: 87–93.
Chu P, Wu E, Weiss LM . (2000). Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 13: 962–972.
Chu PG, Weiss LM . (2002a). Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 15: 6–10.
Chu PG, Weiss LM . (2002b). Keratin expression in human tissues and neoplasms. Histopathology 40: 403–439.
Chu YW, Runyan RB, Oshima RG, Hendrix MJ . (1993). Expression of complete keratin filaments in mouse L cells augments cell migration and invasion. Proc Natl Acad Sci USA 90: 4261–4265.
Chu YW, Seftor EA, Romer LH, Hendrix MJ . (1996). Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility. Am J Pathol 148: 63–69.
Coulombe PA, Hutton ME, Letai A, Hebert A, Paller AS, Fuchs E . (1991). Point mutations in human keratin 14 genes of epidermolysis bullosa simplex patients: genetic and functional analyses. Cell 66: 1301–1311.
Coulombe PA, Omary MB . (2002). ‘Hard‘ and ‘soft‘ principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol 14: 110–122.
Cress AE, Roberts RA, Bowden GT, Dalton WS . (1988). Modification of keratin by the chemotherapeutic drug mitoxantrone. Biochem Pharmacol 37: 3043–3046.
Felder E, Siebenbrunner M, Busch T, Fois G, Miklavc P, Walther P et al. (2008). Mechanical strain of alveolar type II cells in culture: changes in the transcellular cytokeratin network and adaptations. Am J Physiol Lung Cell Mol Physiol 295: L849–L857.
Fickert P, Trauner M, Fuchsbichler A, Stumptner C, Zatloukal K, Denk H . (2003). Mallory body formation in primary biliary cirrhosis is associated with increased amounts and abnormal phosphorylation and ubiquitination of cytokeratins. J Hepatol 38: 387–394.
Fields AP, Regala RP . (2007). Protein kinase C iota: human oncogene, prognostic marker and therapeutic target. Pharmacol Res 55: 487–497.
Fortier AM, Van Themsche C, Asselin E, Cadrin M . (2010). Akt isoforms regulate intermediate filament protein levels in epithelial carcinoma cells. FEBS Lett 584: 984–988.
Fuchs E, Cleveland DW . (1998). A structural scaffolding of intermediate filaments in health and disease. Science 279: 514–519.
Gilbert S, Loranger A, Daigle N, Marceau N . (2001). Simple epithelium keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The protection occurs through a receptor-targeting modulation. J Cell Biol 154: 763–773.
Glotzer M . (2009). The 3Ms of central spindle assembly: microtubules, motors and MAPs. Nat Rev Mol Cell Biol 10: 9–20.
Gonzalvez F, Ashkenazi A . (2010). New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 29: 4752–4765.
Habtezion A, Toivola DM, Butcher EC, Omary MB . (2005). Keratin-8-deficient mice develop chronic spontaneous Th2 colitis amenable to antibiotic treatment. J Cell Sci 118: 1971–1980.
Hammer E, Bien S, Salazar MG, Steil L, Scharf C, Hildebrandt P et al. (2010). Proteomic analysis of doxorubicin-induced changes in the proteome of HepG2cells combining 2-D DIGE and LC-MS/MS approaches. Proteomics 10: 99–114.
Harada M, Strnad P, Toivola DM, Omary MB . (2008). Autophagy modulates keratin-containing inclusion formation and apoptosis in cell culture in a context-dependent fashion. Exp Cell Res 314: 1753–1764.
He T, Stepulak A, Holmstrom TH, Omary MB, Eriksson JE . (2002). The intermediate filament protein keratin 8 is a novel cytoplasmic substrate for c-Jun N-terminal kinase. J Biol Chem 277: 10767–10774.
Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R et al. (2001). Gene-expression profiles in hereditary breast cancer. N Engl J Med 344: 539–548.
Hembrough TA, Vasudevan J, Allietta MM, Glass II WF, Gonias SL . (1995). A cytokeratin 8-like protein with plasminogen-binding activity is present on the external surfaces of hepatocytes, HepG2 cells and breast carcinoma cell lines. J Cell Sci 108 (Part 3): 1071–1082.
Hendrix MJ, Seftor EA, Seftor RE, Trevor KT . (1997). Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 150: 483–495.
Herrmann H, Bar H, Kreplak L, Strelkov SV, Aebi U . (2007). Intermediate filaments: from cell architecture to nanomechanics. Nat Rev Mol Cell Biol 8: 562–573.
Herrmann H, Strelkov SV, Burkhard P, Aebi U . (2009). Intermediate filaments: primary determinants of cell architecture and plasticity. J Clin Invest 119: 1772–1783.
Hernandez BY, Frierson HF, Moskaluk CA, Li YJ, Clegg L, Cote TR et al. (2005). CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray. Hum Pathol 36: 275–281.
Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M et al. (2007). Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 25: 5194–5202.
Irvine AD, Corden LD, Swensson O, Swensson B, Moore JE, Frazer DG et al. (1997). Mutations in cornea-specific keratin K3 or K12 genes cause Meesmann's corneal dystrophy. Nat Genet 16: 184–187.
Iwaya K, Ogawa H, Mukai Y, Iwamatsu A, Mukai K . (2003). Ubiquitin-immunoreactive degradation products of cytokeratin 8/18 correlate with aggressive breast cancer. Cancer Sci 94: 864–870.
Jaitovich A, Mehta S, Na N, Ciechanover A, Goldman RD, Ridge KM . (2008). Ubiquitin-proteasome-mediated degradation of keratin intermediate filaments in mechanically stimulated A549 cells. J Biol Chem 283: 25348–25355.
Kao WW, Liu CY, Converse RL, Shiraishi A, Kao CW, Ishizaki M et al. (1996). Keratin 12-deficient mice have fragile corneal epithelia. Invest Ophthalmol Vis Sci 37: 2572–2584.
Karantza-Wadsworth V, Patel S, Kravchuk O, Chen G, Mathew R, Jin S et al. (2007). Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 21: 1621–1635.
Karantza-Wadsworth V, White E . (2008). A mouse mammary epithelial cell model to identify molecular mechanisms regulating breast cancer progression. Methods Enzymol 446: 61–76.
Katsuragi K, Yashiro M, Sawada T, Osaka H, Ohira M, Hirakawa K . (2007). Prognostic impact of PCR-based identification of isolated tumour cells in the peritoneal lavage fluid of gastric cancer patients who underwent a curative R0 resection. Br J Cancer 97: 550–556.
Kim S, Wong P, Coulombe PA . (2006). A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature 441: 362–365.
Knosel T, Emde V, Schluns K, Schlag PM, Dietel M, Petersen I . (2006). Cytokeratin profiles identify diagnostic signatures in colorectal cancer using multiplex analysis of tissue microarrays. Cell Oncol 28: 167–175.
Kongara S, Kravchuk O, Teplova I, Lozy F, Schulte J, Moore D et al. (2010). Autophagy regulates keratin 8 homeostasis in mammary epithelial cells and in breast tumors. Mol Cancer Res 8: 873–884.
Ku NO, Azhar S, Omary MB . (2002a). Keratin 8 phosphorylation by p38 kinase regulates cellular keratin filament reorganization: modulation by a keratin 1-like disease causing mutation. J Biol Chem 277: 10775–10782.
Ku NO, Darling JM, Krams SM, Esquivel CO, Keeffe EB, Sibley RK et al. (2003a). Keratin 8 and 18 mutations are risk factors for developing liver disease of multiple etiologies. Proc Natl Acad Sci USA 100: 6063–6068.
Ku NO, Gish R, Wright TL, Omary MB . (2001). Keratin 8 mutations in patients with cryptogenic liver disease. N Engl J Med 344: 1580–1587.
Ku NO, Michie S, Oshima RG, Omary MB . (1995). Chronic hepatitis, hepatocyte fragility, and increased soluble phosphoglycokeratins in transgenic mice expressing a keratin 18 conserved arginine mutant. J Cell Biol 131: 1303–1314.
Ku NO, Michie S, Resurreccion EZ, Broome RL, Omary MB . (2002b). Keratin binding to 14-3-3 proteins modulates keratin filaments and hepatocyte mitotic progression. Proc Natl Acad Sci USA 99: 4373–4378.
Ku NO, Omary MB . (2000). Keratins turn over by ubiquitination in a phosphorylation-modulated fashion. J Cell Biol 149: 547–552.
Ku NO, Omary MB . (2006). A disease- and phosphorylation-related nonmechanical function for keratin 8. J Cell Biol 174: 115–125.
Ku NO, Soetikno RM, Omary MB . (2003b). Keratin mutation in transgenic mice predisposes to Fas but not TNF-induced apoptosis and massive liver injury. Hepatology 37: 1006–1014.
Ku NO, Strnad P, Zhong BH, Tao GZ, Omary MB . (2007). Keratins let liver live: mutations predispose to liver disease and crosslinking generates Mallory–Denk bodies. Hepatology 46: 1639–1649.
Ku NO, Wright TL, Terrault NA, Gish R, Omary MB . (1997). Mutation of human keratin 18 in association with cryptogenic cirrhosis. J Clin Invest 99: 19–23.
Ku NO, Zhou X, Toivola DM, Omary MB . (1999). The cytoskeleton of digestive epithelia in health and disease. Am J Physiol 277: G1108–G1137.
Lane EB, McLean WH . (2004). Keratins and skin disorders. J Pathol 204: 355–366.
Lane EB, Rugg EL, Navsaria H, Leigh IM, Heagerty AH, Ishida-Yamamoto A et al. (1992). A mutation in the conserved helix termination peptide of keratin 5 in hereditary skin blistering. Nature 356: 244–246.
Lehr HA, Folpe A, Yaziji H, Kommoss F, Gown AM . (2000). Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 114: 190–196.
Liao J, Ku NO, Omary MB . (1997). Stress, apoptosis, and mitosis induce phosphorylation of human keratin 8 at Ser-73 in tissues and cultured cells. J Biol Chem 272: 17565–17573.
Linder S, Olofsson MH, Herrmann R, Ulukaya E . (2010). Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Rev Mol Diagn 10: 353–359.
Liu F, Chen Z, Wang J, Shao X, Cui Z, Yang C et al. (2008a). Overexpression of cell surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. Neoplasia 10: 1275–1284.
Liu F, Fan D, Qi J, Zhu H, Zhou Y, Yang C et al. (2008b). Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line. Life Sci 83: 496–501.
Liu L, Qian J, Singh H, Meiers I, Zhou X, Bostwick DG . (2007). Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med 131: 1290–1297.
Lloyd C, Yu QC, Cheng J, Turksen K, Degenstein L, Hutton E et al. (1995). The basal keratin network of stratified squamous epithelia: defining K15 function in the absence of K14. J Cell Biol 129: 1329–1344.
Loranger A, Duclos S, Grenier A, Price J, Wilson-Heiner M, Baribault H et al. (1997). Simple epithelium keratins are required for maintenance of hepatocyte integrity. Am J Pathol 151: 1673–1683.
Magin TM, Schroder R, Leitgeb S, Wanninger F, Zatloukal K, Grund C et al. (1998). Lessons from keratin 18 knockout mice: formation of novel keratin filaments, secondary loss of keratin 7 and accumulation of liver-specific keratin 8-positive aggregates. J Cell Biol 140: 1441–1451.
Mashukova A, Oriolo AS, Wald FA, Casanova ML, Kroger C, Magin TM et al. (2009). Rescue of atypical protein kinase C in epithelia by the cytoskeleton and Hsp70 family chaperones. J Cell Sci 122: 2491–2503.
Matros E, Bailey G, Clancy T, Zinner M, Ashley S, Whang E et al. (2006). Cytokeratin 20 expression identifies a subtype of pancreatic adenocarcinoma with decreased overall survival. Cancer 106: 693–702.
McGregor DK, Wu TT, Rashid A, Luthra R, Hamilton SR . (2004). Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol 28: 712–718.
Meng Y, Wu Z, Yin X, Zhao Y, Chen M, Si Y et al. (2009). Keratin 18 attenuates estrogen receptor alpha-mediated signaling by sequestering LRP16 in cytoplasm. BMC Cell Biol 10: 96.
Mertz KD, Demichelis F, Sboner A, Hirsch MS, Dal Cin P, Struckmann K et al. (2008). Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer. Int J Cancer 123: 569–576.
Mizuuchi E, Semba S, Kodama Y, Yokozaki H . (2009). Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression. Int J Cancer 124: 1802–1810.
Moll R, Divo M, Langbein L . (2008). The human keratins: biology and pathology. Histochem Cell Biol 129: 705–733.
Moll R, Franke WW, Schiller DL, Geiger B, Krepler R . (1982). The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11–24.
Moll R, Lowe A, Laufer J, Franke WW . (1992). Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 140: 427–447.
Moll R, Schiller DL, Franke WW . (1990). Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol 111: 567–580.
Na N, Chandel NS, Litvan J, Ridge KM . (2010). Mitochondrial reactive oxygen species are required for hypoxia-induced degradation of keratin intermediate filaments. FASEB J 24: 799–809.
Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, White E . (2004). Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 18: 2095–2107.
Nikitakis NG, Tosios KI, Papanikolaou VS, Rivera H, Papanicolaou SI, Ioffe OB . (2004). Immunohistochemical expression of cytokeratins 7 and 20 in malignant salivary gland tumors. Mod Pathol 17: 407–415.
Obermajer N, Doljak B, Kos J . (2009). Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness. Mol Cancer 8: 88.
Omary MB, Coulombe PA, McLean WH . (2004). Intermediate filament proteins and their associated diseases. N Engl J Med 351: 2087–2100.
Omary MB, Ku NO, Liao J, Price D . (1998). Keratin modifications and solubility properties in epithelial cells and in vitro. Subcell Biochem 31: 105–140.
Omary MB, Ku NO, Strnad P, Hanada S . (2009). Toward unraveling the complexity of simple epithelial keratins in human disease. J Clin Invest 119: 1794–1805.
Omary MB, Ku NO, Tao GZ, Toivola DM, Liao J . (2006). ‘Heads and tails’ of intermediate filament phosphorylation: multiple sites and functional insights. Trends Biochem Sci 31: 383–394.
Oriolo AS, Wald FA, Ramsauer VP, Salas PJ . (2007). Intermediate filaments: a role in epithelial polarity. Exp Cell Res 313: 2255–2264.
Peters B, Kirfel J, Bussow H, Vidal M, Magin TM . (2001). Complete cytolysis and neonatal lethality in keratin 5 knockout mice reveal its fundamental role in skin integrity and in epidermolysis bullosa simplex. Mol Biol Cell 12: 1775–1789.
Pollard TD, Cooper JA . (2009). Actin, a central player in cell shape and movement. Science 326: 1208–1212.
Quinlan RA, Cohlberg JA, Schiller DL, Hatzfeld M, Franke WW . (1984). Heterotypic tetramer (A2D2) complexes of non-epidermal keratins isolated from cytoskeletons of rat hepatocytes and hepatoma cells. J Mol Biol 178: 365–388.
Ridge KM, Linz L, Flitney FW, Kuczmarski ER, Chou YH, Omary MB et al. (2005). Keratin 8 phosphorylation by protein kinase C delta regulates shear stress-mediated disassembly of keratin intermediate filaments in alveolar epithelial cells. J Biol Chem 280: 30400–30405.
Riopel CL, Butt I, Omary MB . (1993). Method of cell handling affects leakiness of cell surface labeling and detection of intracellular keratins. Cell Motil Cytoskeleton 26: 77–87.
Rolli CG, Seufferlein T, Kemkemer R, Spatz JP . (2010). Impact of tumor cell cytoskeleton organization on invasiveness and migration: a microchannel-based approach. PLoS One 5: e8726.
Schmitz-Winnenthal FH, Volk C, Helmke B, Berger S, Hinz U, Koch M et al. (2006). Expression of cytokeratin-20 in pancreatic cancer: an indicator of poor outcome after R0 resection. Surgery 139: 104–108.
Schutte B, Henfling M, Kolgen W, Bouman M, Meex S, Leers MP et al. (2004). Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 297: 11–26.
Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin TM et al. (2006). New consensus nomenclature for mammalian keratins. J Cell Biol 174: 169–174.
Sivaramakrishnan S, DeGiulio JV, Lorand L, Goldman RD, Ridge KM . (2008). Micromechanical properties of keratin intermediate filament networks. Proc Natl Acad Sci USA 105: 889–894.
Sivaramakrishnan S, Schneider JL, Sitikov A, Goldman RD, Ridge KM . (2009). Shear stress induced reorganization of the keratin intermediate filament network requires phosphorylation by protein kinase C zeta. Mol Biol Cell 20: 2755–2765.
Smith F . (2003). The molecular genetics of keratin disorders. Am J Clin Dermatol 4: 347–364.
Soeth E, Grigoleit U, Moellmann B, Roder C, Schniewind B, Kremer B et al. (2005). Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT–PCR indicates poor survival. J Cancer Res Clin Oncol 131: 669–676.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869–10874.
Stacey SN, Sulem P, Masson G, Gudjonsson SA, Thorleifsson G, Jakobsdottir M et al. (2009). New common variants affecting susceptibility to basal cell carcinoma. Nat Genet 41: 909–914.
Stefansson IM, Salvesen HB, Akslen LA . (2006). Loss of p63 and cytokeratin 5/6 expression is associated with more aggressive tumors in endometrial carcinoma patients. Int J Cancer 118: 1227–1233.
Steinert PM, Marekov LN, Parry DA . (1993). Conservation of the structure of keratin intermediate filaments: molecular mechanism by which different keratin molecules integrate into preexisting keratin intermediate filaments during differentiation. Biochemistry 32: 10046–10056.
Strnad P, Zhou Q, Hanada S, Lazzeroni LC, Zhong BH, So P et al. (2010). Keratin variants predispose to acute liver failure and adverse outcome: race and ethnic associations. Gastroenterology 139: 828–835, 835 e1–e3.
Styers ML, Kowalczyk AP, Faundez V . (2005). Intermediate filaments and vesicular membrane traffic: the odd couple's first dance? Traffic 6: 359–365.
Suresh S, Spatz J, Mills JP, Micoulet A, Dao M, Lim CT et al. (2005). Connections between single-cell biomechanics and human disease states: gastrointestinal cancer and malaria. Acta Biomater 1: 15–30.
Takahashi K, Paladini RD, Coulombe PA . (1995). Cloning and characterization of multiple human genes and cDNAs encoding highly related type II keratin 6 isoforms. J Biol Chem 270: 18581–18592.
Toivola DM, Ku NO, Resurreccion EZ, Nelson DR, Wright TL, Omary MB . (2004). Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease. Hepatology 40: 459–466.
Toivola DM, Nakamichi I, Strnad P, Michie SA, Ghori N, Harada M et al. (2008). Keratin overexpression levels correlate with the extent of spontaneous pancreatic injury. Am J Pathol 172: 882–892.
Toivola DM, Strnad P, Habtezion A, Omary MB . (2010). Intermediate filaments take the heat as stress proteins. Trends Cell Biol 20: 79–91.
Toivola DM, Tao GZ, Habtezion A, Liao J, Omary MB . (2005). Cellular integrity plus: organelle-related and protein-targeting functions of intermediate filaments. Trends Cell Biol 15: 608–617.
Toivola DM, Zhou Q, English LS, Omary MB . (2002). Type II keratins are phosphorylated on a unique motif during stress and mitosis in tissues and cultured cells. Mol Biol Cell 13: 1857–1870.
Treiber M, Schulz HU, Landt O, Drenth JP, Castellani C, Real FX et al. (2006). Keratin 8 sequence variants in patients with pancreatitis and pancreatic cancer. J Mol Med 84: 1015–1022.
Uenishi T, Yamazaki O, Tanaka H, Takemura S, Yamamoto T, Tanaka S et al. (2008). Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol 15: 583–589.
Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M . (2007). The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 56: 399–404.
van den IP, Norman DG, Quinlan RA . (1999). Molecular chaperones: small heat shock proteins in the limelight. Curr Biol 9: R103–R105.
van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J et al. (2002). Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161: 1991–1996.
Vijayaraj P, Kroger C, Reuter U, Windoffer R, Leube RE, Magin TM . (2009). Keratins regulate protein biosynthesis through localization of GLUT1 and -3 upstream of AMP kinase and Raptor. J Cell Biol 187: 175–184.
Vijayaraj P, Sohl G, Magin TM . (2007). Keratin transgenic and knockout mice: functional analysis and validation of disease-causing mutations. Methods Mol Biol 360: 203–251.
Wang J, Chan JY, Fong CC, Tzang CH, Fung KP, Yang M . (2009). Transcriptional analysis of doxorubicin-induced cytotoxicity and resistance in human hepatocellular carcinoma cell lines. Liver Int 29: 1338–1347.
Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H et al. (2009). Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 27: 1549–1556.
Winter H, Langbein L, Praetzel S, Jacobs M, Rogers MA, Leigh IM et al. (1998). A novel human type II cytokeratin, K6hf, specifically expressed in the companion layer of the hair follicle. J Invest Dermatol 111: 955–962.
Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, van Diest P et al. (2003). Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 63: 5679–5684.
Woelfle U, Sauter G, Santjer S, Brakenhoff R, Pantel K . (2004). Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res 10: 2670–2674.
Woll S, Windoffer R, Leube RE . (2007). p38 MAPK-dependent shaping of the keratin cytoskeleton in cultured cells. J Cell Biol 177: 795–807.
Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S et al. (2009). Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 27: 2177–2184.
Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H . (2009). Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 16: 260–267.
Yang XR, Xu Y, Shi GM, Fan J, Zhou J, Ji Y et al. (2008). Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res 14: 3850–3859.
Yano S, Komine M, Fujimoto M, Okochi H, Tamaki K . (2004). Mechanical stretching in vitro regulates signal transduction pathways and cellular proliferation in human epidermal keratinocytes. J Invest Dermatol 122: 783–790.
Yaziji H, Battifora H, Barry TS, Hwang HC, Bacchi CE, McIntosh MW et al. (2006). Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 19: 514–523.
Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A et al. (2001). Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 61: 5168–5178.
Zatloukal K, French SW, Stumptner C, Strnad P, Harada M, Toivola DM et al. (2007). From Mallory to Mallory–Denk bodies: what, how and why? Exp Cell Res 313: 2033–2049.
Zatloukal K, Stumptner C, Lehner M, Denk H, Baribault H, Eshkind LG et al. (2000). Cytokeratin 8 protects from hepatotoxicity, and its ratio to cytokeratin 18 determines the ability of hepatocytes to form Mallory bodies. Am J Pathol 156: 1263–1274.
Acknowledgements
This work was supported by NIH Grant R00CA133181 and a Damon Runyon Clinical Investigator Award (VK).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no conflict of interest
Rights and permissions
About this article
Cite this article
Karantza, V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 30, 127–138 (2011). https://doi.org/10.1038/onc.2010.456
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.456
Keywords
This article is cited by
-
PDE3B regulates KRT6B and increases the sensitivity of bladder cancer cells to copper ionophores
Naunyn-Schmiedeberg's Archives of Pharmacology (2024)
-
Interstitial Cystitis/Bladder Pain Syndrome: Role of Bladder Inflammation in Bladder Function
Current Bladder Dysfunction Reports (2024)
-
Proteomic interrogation of the meninges reveals the molecular identities of structural components and regional distinctions along the CNS axis
Fluids and Barriers of the CNS (2023)
-
Variability of serum CYFRA 21 − 1 and its susceptibility to clinical characteristics in individuals without cancer: a 4-year retrospective analysis
BMC Pulmonary Medicine (2023)
-
Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma
Molecular Cancer (2023)
